💊💊TWEETORIAL ALERT💊💊
New work out this evening in @NEJM@NEJMPerspec on the plan to redesign #Medicare#PartD and how much savings there might be for people enrolled in the program! This has been a moving target (I'm looking at you #BuildBackBetter)! I've got you covered! 1/7
I calculated savings relative to the 2022 benefit for the top 15 highest spending drugs in Part D for the major bills introduced that aimed to redesign the program. None are an exact fit, but HR3 is maybe the closest given the $2000 cap. Some details are still unknown. 2/7
Most people won't save very much, though it depends on some of those "TBD" details. That's actually OK because MOST #Medicare beneficiaries actually like the benefit! It works on average really well. 3/7
BUT, if you need an expensive drug you are going to REALLY see savings. Like 70-80% less spending out-of-pocket, depending on the final details and how much spending you have. This is HUGE for people needing cancer drugs and drugs for other complex illnesses. 4/7
For everyone else, you get to have the FINANCIAL SECURITY of not having to spend all of your money on a drug if you happen to need one that is very expensive. That's kind of the point of health insurance. It is why EVERYONE should support a cap. 5/7
Thank you to the members of Congress who have kept drug pricing and access reform alive in #BuildBackBetter#BuildBackBetterAct and the amazing staff and members who are focused on getting the details right! 6/7
Thank you to @Arnold_Ventures@commonwealthfnd and @LLSusa who have supported my time to do drug policy work, and specifically on Part D. I hope that beneficiaries will get some of the relief needed with this bill! 7/7.
You might remember headlines like this one that were telling us about companies coming out with generic versions of their $$$$ brand-name drugs. We saw this for #insulin#hepatitisC and #epipen over the past few years. 2/7 nytimes.com/2019/03/04/hea…
These are "authorized generics" which are when a brand company takes off the brand name but the drug is exactly the same. In these cases, the generic product came out way before patents were expired. 3/7
Last week my mom was diagnosed with metastatic (stage IV) breast cancer. As someone who has worked in the pharmaceutical industry, studies cancer drug prices, and is trained as a health services researcher, I have some thoughts to share about our current system. 1/10
First, #Cancer sucks. Metastatic cancer is something I hope you never have to say to or hear from someone that you love. When it is you, or your loved one, you desperately want more time. You want good quality of life, and you need for them to live. 2/10
The subtype of cancer tells you what treatment options you have in this really awful situation. If you have orally administered options or infused options, for example. Some subtypes have great targeted therapies that extend life and "are well tolerated". 3/10
Our big finding: If you need a lot of drugs or some very expensive drugs you would save more money out-of-pocket by using brands instead of generics. 2/10
Yeah, that's right. That doesn't make sense.
This happens because branded drug companies pay discounts in the doughnut hole that count as out-of-pocket spending. Generic drug makers don’t. 3/10